Dupilumab was linked to improved lung function, asthma control, QOL, and biomarkers for up to 2 years in patients with uncontrolled severe asthma.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use has recommended the granting of a marketing authorization for Exdensur (depemokimab, GlaxoSmithKline) for severe ...

Severe asthma affects roughly 2 million people in the United States. It is hard to control — even with inhaled steroid medicines and additional therapies. More than 80% of cases are linked to type 2 ...

Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly across different ages and early-life risk profiles. This evidence gap ...

Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...

GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick relief and daily control.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

The addition of tezepelumab to standard treatment allowed half the adults with severe asthma to discontinue their use of oral corticosteroids (OCS) after 1 year, according to new data from nearly 300 ...

Please provide your email address to receive an email when new articles are posted on . The questionnaire assessed general fatigue, sleep-rest fatigue and cognitive fatigue. Asthma-related quality of ...